Kv7 channels as targets for the treatment of pain

Current Pharmaceutical Design

Volumn 15, Issue 15, 2009, Pages 1773-1798

  Wickenden, A D ^a   McNaughton Smith, G ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Instituto Universitario de Bio Organica Antonio Gonzalez   (Spain)

Author keywords

Flupirtine; ICA 27243; KCNQ; Kv7; Pain; Potassium channels; Retigabine

Indexed keywords

1,3 PHENYLENEDIAMINE DERIVATIVE; 10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; 3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 4 (N AZACYCLOALKYL)ANILIDE DERIVATIVE; 5 CARBOXAMIDE THIAZOLE DERIVATIVE; 5 PYRIMIDINECARBOXAMIDE DERIVATIVE; ALPHA METHYLBENZYLAMINE CINNAMIDE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; DICLOFENAC; FLUPIRTINE; IBUPROFEN; ICA 105665; ICA 27243; ICA 69673; MECLOFENAMIC ACID; METANOR; N (6 CHLOROPYRIDIN 3 YL) 3,4 DIFLUOROBENZAMIDE; NH 6; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNQ5; POTASSIUM CHANNEL KV7; POTASSIUM CHANNEL KV7.2; POTASSIUM CHANNEL KV7.3; POTASSIUM CHANNEL STIMULATING AGENT; PYRITHIONE ZINC; QUINAZOLINE DERIVATIVE; QUINOLINONE DERIVATIVE; RETIGABINE; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ANALGESIC AGENT; POTASSIUM CHANNEL KCNQ;

ALLODYNIA; ANALGESIC ACTIVITY; ATAXIA; BLURRED VISION; BRAIN CORTEX; CANCER PAIN; CLINICAL TRIAL; CONFUSION; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG WITHDRAWAL; DYSARTHRIA; EPILEPSY; EPISIOTOMY PAIN; FATIGUE; FIBROMYALGIA; FOCAL EPILEPSY; GENE EXPRESSION; GRAND MAL SEIZURE; HUMAN; HYPERALGESIA; LOW BACK PAIN; MIGRAINE; MUSCULOSKELETAL PAIN; MYELINATED NERVE; NAUSEA; NERVE EXCITABILITY; NERVE INJURY; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; NONMYELINATED NERVE; PAIN; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PRURITUS; REVIEW; SOMNOLENCE; SPINAL CORD DORSAL HORN; SPINAL GANGLION; SPORT INJURY; STRUCTURE ACTIVITY RELATION; THALAMUS; TREMOR; XEROSTOMIA; ANIMAL; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY;

ANALGESICS; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; KCNQ POTASSIUM CHANNELS; NEURONS; PAIN;

EID: 67650577094     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788186326     Document Type: Review

References (142)

1. Delmas P, Brown DA. Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 2005; 6(11): 850-62.
2. Robbins J. KCNQ potassium channels: Physiology, pathophysiology, and pharmacology. Pharmacol Ther 2001; 90(1): 1-19.
3. Jentsch TJ. Neuronal KCNQ potassium channels: Physiology and role in disease. Nat Rev Neurosci 2000; 1(1): 21-30.
4. Kharkovets T, Hardelin JP, Safieddine S, Schweizer M, El-Amraoui A, Petit C, et al. KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci USA 2000; 97(8): 4333-8.
5. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, et al. A potassium channel mutation in neonatal human epilepsy. Science 1998; 279(5349): 403-6.
6. Charlier C, Singh NA, Ryan SG, Lewis TB, Reus BE, Leach RJ, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet 1998; 18(1): 53-5.
7. Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998; 18(1): 25-9.
8. Rogawski MA. KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: Implications for therapy. Trends Neurosci 2000; 23(9): 393-8.
9. Wickenden A, Roeloffs R, McNaughton-Smith G, Rigdon GC. KCNQ potassium channels: Drug targets for the treatment of epilepsy and pain. Expert Opin Therapeut Patents 2004; 14: 457-69.
10. Aiken SP, Lampe BJ, Murphy PA, Brown BS. Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer. Br J Pharmacol 1995; 115(7): 1163-8.
11. Lamas JA, Selyanko AA, Brown DA. Effects of a cognition-enhancer, linopirdine (DuP 996), on M-type potassium currents (IK(M)) and some other voltage- and ligand-gated membrane currents in rat sympathetic neurons. Eur J Neurosci 1997; 9(3): 605-16.
12. Schnee ME, Brown BS. Selectivity of linopirdine (DuP 996), a neurotransmitter release enhancer, in blocking voltage-dependent and calcium-activated potassium currents in hippocampal neurons. J Pharmacol Exp Ther 1998; 286(2): 709-17.
13. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, et al. KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel. Science 1998; 282(5395): 1890-3.
14. Wickenden AD, Zou A, Wagoner PK, Jegla T. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 2001; 132(2): 381-4.
15. Zaczek R, Chorvat RJ, Saye JA, Pierdomenico ME, Maciag CM, Logue AR, et al. Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: Comparison to linopirdine. J Pharmacol Exp Ther 1998; 285(2): 724-30.
16. Earl RA, Zaczek R, Teleha CA, Fisher BN, Maciag CM, Marynowski ME, et al. 2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action. J Med Chem 1998; 41(23): 4615-22.
17. Rundfeldt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur J Pharmacol 1997; 336(2-3): 243-9.
18. Rundfeldt C. Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells. Epilepsy Res 1999; 35(2): 99-107.
19. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci Lett 2000; 282(1-2): 73-6.
20. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000; 58(3): 591-600.
21. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000; 58(2): 253-62.
22. Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 2001; 21(15): 5535-45.
23. Passmore GM, Selyanko AA, Mistry M, Al-Qatari M, Marsh SJ, Matthews EA, et al. KCNQ/M currents in sensory neurons: Significance for pain therapy. J Neurosci 2003; 23(18): 7227-36.
24. Kapetanovic IM, Yonekawa WD, Kupferberg HJ. The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro. Epilepsy Res 1995; 22(3): 167-73
25. Rundfeldt C AV, Heinnemann U. Multiple actions of the new anticonvulsant D-23129 on voltage-gated inward currents and GABA-induced currents in cultured neuronal cells.. Naunyn-Schmiedeberg's Arch Pharmacol 1995; 351(Suppl): R160.
26. Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993; 45(4): 548-69.
27. Wickenden AD, Krajewski JL, London B, Wagoner PK, Wilson WA, Clark S, et al. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): A novel, selective KCNQ2/Q3 potassium channel activator. Mol Pharmacol 2008; 73(3): 977-86.
28. Roeloffs R, Wickenden AD, Crean C, Werness S, McNaughton-Smith G, Stables J, et al. In vivo profile of ICA-27243, a potent and selective KCNQ2/Q3 activator in rodent anticonvulsant models. J Pharmacol Exp Ther 2008; 326(3): 818-28.
29. Martire M, Castaldo P, D'Amico M, Preziosi P, Annunziato L, Taglialatela M. M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals. J Neurosci 2004; 24(3): 592-7.
30. Wladyka CL, Feng B, Glazebrook PA, Schild JH, Kunze DL. The KCNQ/ M-current modulates arterial baroreceptor function at the sensory terminal in rats. J Physiol 2008; 586(3): 795-802.
31. Passmore G, and Brown, DA. Effects of M-channel modulators on peripheral excitability in rat hairy skin. Soc Neurosci Abstr 2007; 681: 8.
32. Wickenden A, Ye F, Liu Y, McNaugton-Smith G, Roeloffs R, Rigdon GC. KCNQ Channel expression in rat DRG following nerve ligation. Soc Neurosci Abstr 2002; 454: 7.
33. Wladyka CL, Kunze DL. KCNQ/M-currents contribute to the resting membrane potential in rat visceral sensory neurons. J Physiol 2006; 575(Pt 1): 175-89.
34. Gerlach A, Stoehr SJ, Rigdon GC. Sub-type selective activation of KCNQ2/ 3 channels modulates the excitability of nociceptive dorsal root ganglion neurons. Soc Neurosci Abstr 2007; 509: 7.
35. Rose K, Dalle C, Mucha M, Robertson B, Gamper N. M-channel expression and activity as a possible mechanism controlling excitability of DRG neurons. Soc Neurosci Abstr 2007: 285.16.
36. Devaux JJ, Kleopa KA, Cooper EC, Scherer SS. KCNQ2 is a nodal K+ channel. J Neurosci 2004; 24(5): 1236-44.
37. Schwarz JR, Glassmeier G, Cooper EC, Kao TC, Nodera H, Tabuena D, et al. KCNQ channels mediate IKs, a slow K+ current regulating excitability in the rat node of Ranvier. J Physiol 2006; 573(Pt 1): 17-34.
38. Lang PM, Fleckenstein J, Passmore GM, Brown DA, Grafe P. Retigabine reduces the excitability of unmyelinated peripheral human axons. Neuropharmacology 2008; 54(8): 1271-8.
39. Dedek K, Kunath B, Kananura C, Reuner U, Jentsch TJ, Steinlein OK. Myokymia and neonatal epilepsy caused by a mutation in the voltage sensor of the KCNQ2 K+ channel. Proc Natl Acad Sci USA 2001; 98(21): 12272-7.
40. Rivera-Arconada I, Lopez-Garcia JA. Effects of M-current modulators on the excitability of immature rat spinal sensory and motor neurones. Eur J Neurosci 2005; 22(12): 3091-8.
41. Rivera-Arconada I, Lopez-Garcia JA. Retigabine-induced population primary afferent hyperpolarisation in vitro. Neuropharmacology 2006; 51(4): 756-63.
42. Tinel N, Lauritzen I, Chouabe C, Lazdunski M, Borsotto M. The KCNQ2 potassium channel: Splice variants, functional and developmental expression. Brain localization and comparison with KCNQ3. FEBS Lett 1998; 438(3): 171-6.
43. Saganich MJ, Machado E, Rudy B. Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain. J Neurosci 2001; 21(13): 4609-24.
44. Cooper EC, Harrington E, Jan YN, Jan LY. M channel KCNQ2 subunits are localized to key sites for control of neuronal network oscillations and synchronization in mouse brain. J Neurosci 2001; 21(24): 9529-40.
45. Yus-Najera E, Munoz A, Salvador N, Jensen BS, Rasmussen HB, Defelipe J, et al. Localization of KCNQ5 in the normal and epileptic human temporal neocortex and hippocampal formation. Neuroscience 2003; 120(2): 353-64.
46. Geiger J, Weber YG, Landwehrmeyer B, Sommer C, Lerche H. Immunohistochemical analysis of KCNQ3 potassium channels in mouse brain. Neurosci Lett 2006; 400(1-2): 101-4.
47. Weber YG, Geiger J, Kampchen K, Landwehrmeyer B, Sommer C, Lerche H. Immunohistochemical analysis of KCNQ2 potassium channels in adult and developing mouse brain. Brain Res 2006; 1077(1): 1-6.
48. McCormick DA, Prince DA. Mechanisms of action of acetylcholine in the guinea-pig cerebral cortex in vitro. J Physiol 1986; 375: 169-94.
49. Cooper EC, Aldape KD, Abosch A, Barbaro NM, Berger MS, Peacock WS, et al. Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy. Proc Natl Acad Sci USA 2000; 97(9): 4914-9.
50. Hu H, Vervaeke K, Storm JF. M-channels (Kv7/KCNQ channels) that regulate synaptic integration, excitability, and spike pattern of CA1 pyramidal cells are located in the perisomatic region. J Neurosci 2007; 27(8): 1853-67.
51. Rasmussen HB, Frokjaer-Jensen C, Jensen CS, Jensen HS, Jorgensen NK, Misonou H, et al. Requirement of subunit co-assembly and ankyrin-G for M-channel localization at the axon initial segment. J Cell Sci 2007; 120(Pt 6): 953-63.
52. Rivera-Arconada I, Martinez-Gomez J, Lopez-Garcia JA. Mcurrent modulators alter rat spinal nociceptive transmission: An electrophysiological study in vitro. Neuropharmacology 2004; 46(4): 598-606.
53. Roza C, Lopez-Garcia JA. Retigabine, the specific KCNQ channel opener, blocks ectopic discharges in axotomized sensory fibres. Pain 2008.
54. Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 2003; 460(2-3): 109-16.
55. Munro G, Dalby-Brown W. Kv7 (KCNQ) channel modulators and neuropathic pain. J Med Chem 2007; 50(11): 2576-82.
56. Dost R, Rostock A, Rundfeldt C. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation. Naunyn Schmiedebergs Arch Pharmacol 2004; 369(4): 382-90.
57. Nielsen AN, Mathiesen C, Blackburn-Munro G. Pharmacological characterisation of acid-induced muscle allodynia in rats. Eur J Pharmacol 2004; 487(1-3): 93-103.
58. Hirano K, Kuratani K, Fujiyoshi M, Tashiro N, Hayashi E, Kinoshita M. Kv7.2-7.5 voltage-gated potassium channel (KCNQ2-5) opener, retigabine, reduces capsaicin-induced visceral pain in mice. Neurosci Lett 2007; 413(2): 159-62.
59. Ilyin V, Carlin KP, Hodges DD, Robledo S, Woodward RM. Flupirtine A positive modulator of heteromeric KCNQ2/Q3 channels. Socr Neurosci Abstr 2002: 758.10.
60. Nickel B. The antinociceptive activity of flupirtine: A structurally new analgesic. Postgrad Med J 1987; 63(Suppl 3): 19-28.
61. Gordon R, Sofia RD, Diamantis W. Effect of flupirtine maleate on the nociceptive pathway, EEG, evoked potentials and polysynaptic reflexes in laboratory animals. Postgrad Med J 1987; 63(Suppl 3): 49-55.
62. Carlsson KH, Jurna I. Depression by flupirtine, a novel analgesic agent, of motor and sensory responses of the nociceptive system in the rat spinal cord. Eur J Pharmacol 1987; 143(1): 89-99.
63. Szelenyi I, Nickel B, Borbe HO, Brune K. Mode of antinociceptive action of flupirtine in the rat. Br J Pharmacol 1989; 97(3): 835-42.
64. Swedberg MD. The mouse grid-shock analgesia test: Pharmacological characterization of latency to vocalization threshold as an index of antinociception. J Pharmacol Exp Ther 1994; 269(3): 1021-8.
65. Diamantis W, Gordon R, Sofia RD. Analgesic activity following combined oral administration of flupirtine maleate and peripherally acting analgesics in mice and rats. Postgrad Med J 1987; 63(Suppl 3): 29-34.
66. Nickel B, Jakovlev V, Szelenyi I. [The effect of flupirtine, various analgesics and muscle relaxants on skeletal muscle tone in the conscious rat]. Arzneimittelforschung 1990; 40(8): 909-11.
67. Roeloffs R, Wickenden AD, McNaughton-Smith G, Jones LD, Harrison W, Porreca F, et al. In vivo profile of ICA-27243, a potent and selective KCNQ2/3 activator in rodent models of pain. Socr Neurosci Abstr 2005; 153: 14.
68. Mark L, Harrison, JE, Cummons T, Strassle BW, Smith V, Childers W, et al. Activity of a KCNQ2/3 opener in rat models of neuropathic pain. Soc Neurosci Abstr 2007; 509: 3.
69. Leventhal L, Lu P, Piesla MJ, Harrison J, McDevitt R, Childers W, et al. Activity of a KCNQ2/3 opener in rat models of inflammatory pain. Socr Neurosci Abstr 2007; 509: 17.
70. Luben V, Muller H, Lobisch M, Worz R. Treatment of tumor pain with flupirtine. Results of a double-blind study versus tramadol. Fortschr Med 1994; 112(19): 282-6.
71. Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987; 63(Suppl 3): 67-70.
72. Scheef W, Wolf-Gruber D. [Flupirtine in patients with cancer pain]. Arzneimittelforschung 1985; 35(1): 75-7.
73. Mastronardi P, D'Onofrio M, Scanni E, Pinto M, Frontespezi S, Ceccarelli MG, et al. Analgesic activity of flupirtine maleate: A controlled double-blind study with diclofenac sodium in orthopaedics. J Int Med Res 1988; 16(5): 338-48.
74. Ceccarelli G, Ciampini M, Frontespezi S. Flupirtine: The first Italian experience. Postgrad Med J 1987; 63(Suppl 3): 105-8.
75. Riethmuller-Winzen H. Flupirtine in the treatment of postoperative pain. Postgrad Med J 1987; 63(Suppl 3): 61-5.
76. Moore RA, Bullingham RE, Simpson S, O'Sullivan G, Evans PJ, McQuay HJ, et al. Comparison of flupirtine maleate and dihydrocodeine in patients following surgery. Br J Anaesth 1983; 55(5): 429-32.
77. Worz R, Bolten W, Heller B, Krainick JU, Pergande G. [Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study]. Fortschr Med 1996; 114(35-36): 500-4.
78. Million R, Finlay BR, Whittington JR. Clinical trial of flupirtine maleate in patients with migraine. Curr Med Res Opin 1984; 9(3): 204-12.
79. Stoll AL. Fibromyalgia symptoms relieved by flupirtine: An openlabel case series. Psychosomatics 2000; 41(4): 371-2.
80. Herrmann WM, Kern U, Aigner M. On the adverse reactions and efficacy of long-term treatment with flupirtine: Preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis. Postgrad Med J 1987; 63(Suppl 3): 87-103.
81. McMahon FG, Arndt WF Jr, Newton JJ, Montgomery PA, Perhach JL. Clinical experience with flupirtine in the U.S. Postgrad Med J 1987; 63(Suppl 3): 81-5.
82. Carter-Wallace submitting additional Flupirtine efficacy study, firm tells shareholders; Hoyt family gains voting strength with antitakeover measure. Pink Sheet 1987; 49(Number 030): Page 16
83. Bepridil anti-arrhythmia indication under development, Carter-Wallace notes at annual meeting; McNeil submitting further angina data this year. Pink Sheet 1988; 50(030): 8-9.
84. Khanzhin N, Rottländer M, Watson WP; H Lundbeck A/S. Substituted indoline and indole derivatives. United States patent application WO2004/ 096767. November 11, 2004
85. Rottlander M, Ritzen A, Norgaard MB, Khanzhin N, Tornoe CW; H Lundbeck A/ S. 1,2,4-Triaminobenzene derivatives useful for the treating disorders of the central nervous system. United States patent US20087368472. May 6, 2008.
86. Vernier J-M, De La Rosa MA, Chen H, Wu, JZ, Larson GL Cheney IW; Valeant pharmaceuticals. Derivatives of 4-(Nazacycloalkyl) anilides as potassium channel modulators. United States patent application WO2008/024398. February 28, 2008.
87. Vernier J-M, Ouk S, De La Rosa MA, Paisner DA; Valeant pharmaceuticals. Derivatives of 1,3-diamino benzene as potassium channel modulators. United States patent application WO2008/0045534. February 21, 2008
88. McNaughton-Smith GA, Gross MF, Wickenden AD; Icagen Inc. Benzanilides as potassium channel openers. United States patent US20026372767. April 16, 2002
89. McNaughton-Smith G, Fritch PC, Amato GS; Icagen Inc. Pyridine substituted benzanilides as potassium channel openers. United States patent US20026495550. December 17, 2002.
90. McNaughton-Smith GA, Gross MF, Wickenden AD; Icagen Inc. Benzanilides as potassium channel openers. United States patent US20036605725. August 12, 2003.
91. McNaughton-Smith G. The identification of KCNQ channel modulators and their potential use in disorders associated with excessive neuronal excitability. American Chemical Society meeting abstract, August 28th 2005, Washington DC: USA 2005.
92. McNaughton-Smith GA, Amato GS Icagen Inc. Bisarylamines as potassium channel openers. United States patent US20036593349. July 15, 2003.
93. Dupuis DS, Schroder RL, Jespersen T, Christensen JK, Christophersen P, Jensen BS, et al. Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur J Pharmacol 2002; 437(3): 129-37.
94. Schroder RL, Jespersen T, Christophersen P, Strobaek D, Jensen BS, Olesen SP. KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology 2001; 40(7): 888-98.
95. Schroder RL, Strobaek D, Olesen SP, Christophersen P. Voltage-independent KCNQ4 currents induced by (+/-)BMS-204352. Pflugers Arch 2003; 446(5): 607-16.
96. Jensen BS, SchrØder RL, StrØbæk D, Olesen, SP; Neuro-search A/S. Use of 3-oxindole derivatives as KCNQ potassium channel modulators. United States patent application WO2002/000217. January 3, 2002
97. Hewawasam P, Dextraze P, Gribkoff VK, Kinney GG, Dworetzky SI; Bristol-Myers Squibb Company. Fluoro-oxindole derivatives as modulators of KCNQ potassium channels. United States patent US20026469042. October 22, 2002
98. Hewawasam P, Chen N, Ding M, Natale JT, Boissard CG, Yeola S, et al. The synthesis and structure-activity relationships of 3-amino-4-benzylquinolin-2-ones; discovery of novel KCNQ2 channel openers. Bioorg Med Chem Lett 2004; 14(7): 1615-8.
99. Hewawasam P, Dodd, DS, Weaver, CD, Dextraze P, Gribkoff VK, Kinney GG, Dworetzky SI; Bristol-Myers Squibb Company. 2,4-Disubstituted pyrimidine-5-carboxamides as KCNQ potassium channel modulators. United States patent application WO2002/066036. August 29, 2002
100. Khanzhin N, Greve DR, Rottlander M; Lundbeck Research USA. Substituted pyrimidine derivatives. United States patent application WO2007/0066612. March 22, 2007
101. TornrØe CW, Khanzhin N, Rottländer M, Watson, WP, Greve DR; H. Lundbeck A/S Substituted pyridine derivatives. United States patent application WO2006/092143. September 8, 2006
102. Wu Y-J, Sun L-Q, Chen J, He H, L'Heureux A, Dextraze P, Daris J-P, Kinney GG, Dworetzky SI, Hewawasam, P; Bristol-Myers Squibb Company. Cinnamides as KCNQ potassium channel modulators. United States patent application WO2002/096858. December 5, 2002
103. Wu YJ, Davis CD, Dworetzky S, Fitzpatrick WC, Harden D, He H, et al. Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: Identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition. J Med Chem 2003; 46(18): 3778-81.
104. Wu Y-J, Sun L-Q, He H, L'Heureux, A; Bristol-Myers Squibb Company. 1-Aryl-2-hydroxethyl amides as potassium channel openers. United States patent application WO2004/047743. June 10, 2004
105. Wu Y-J, L'Heureux, A, He H; Bristol-Myers Squibb Company. 3-Heterocyclic benzylamide derivatives as potassium channel openers. United States patent application WO2004/047744. June 10, 2004
106. L'Heureux A, Martel A, He H, Chen J, Sun LQ, Starrett JE, et al. (S,E)-N-[1-(3-heteroarylphenyl)ethyl]-3-(2-fluorophenyl)acrylamides: synthesis and KCNQ2 potassium channel opener activity. Bioorg Med Chem Lett 2005; 15(2): 363-6.
107. Wu Y-J, Sun L-Q, Chen J; Bristol-Myers Squibb Company. 3-(Pyridyl-piperazin-1-yl)-phenethyl amides as potassium channel openers. United States patent application WO2004/047745. June 10, 2004
108. Wu Y-J, Sun L-Q, L'Heureux, A; Bristol-Myers Squibb Company. Arylcyclopropylcarboxylic amides as potassium channel openers. United States patent application WO2004/047738. June 10, 2004
109. Wu YJ, Boissard CG, Greco C, Gribkoff VK, Harden DG, He H, et al. (S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: An orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. J Med Chem 2003; 46(15): 3197-200.
110. Bentzen BH, Schmitt N, Calloe K, Dalby Brown W, Grunnet M, Olesen SP. The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology 2006; 51(6): 1068-77.
111. Wu YJ, He H, Sun LQ, L'Heureux A, Chen J, Dextraze P, et al. Synthesis and structure-activity relationship of acrylamides as KCNQ2 potassium channel openers. J Med Chem 2004; 47(11): 2887-96.
112. Boy K, Wu Y-J, Guernon JM; Bristol-Myers Squibb Company. 2-Aryl thiazole derivatives KCNQ modulators. United States patent application WO2004/ 060281. July 22, 2004
113. Boy K, Wu Y-J; Bristol-Myers Squibb Company. Aminoalkyl thiazole derivatives KCNQ modulators. United States patent application WO2004/ 0138268. July 15, 2004
114. Boy K, Wu Y-J; Bristol-Myers Squibb Company. Aminoalkyl thiazole derivatives KCNQ modulators. United States patent application WO2004/ 0138268. July 15, 2004
115. McNaughton-Smith G. Novel KCNQ agonists as potential new therapeutics. SERMACS: Atlanta 2003.
116. McNaughton-Smith GA, Thomas JB, Amato, G; Icagen, Inc. Quinazolinones as potassium channel modulators. United States patent application WO2004/ 058704. July 15, 2004
117. McNaughton-Smith GA, Amato GS, Thomas JB; Icagen, Inc. Fused ring heterocycles as potassium channel modulators. United States patent US7223768. May 29, 2007.
118. McNaughton-Smith GA, Amato GS, Thomas JB; Icagen, Inc. Fused ring heterocycles as potassium channel modulators. United States patent application WO2008/0058319. March 6, 2008.
119. Brown WD, Jessen, C, Demnitz J, Dyhring T, StrØbæk D; Neurosearch A/S. Quniazolinones and their use as potassium channel activators. United States patent application WO2007/104717. September 20, 2007
120. Brown WD, Teuber, L, Dyhring T, StrØbæÆk D, Jessen, C; Neurosearch A/S. Novel quinazoline derivatives and their medical use. United States patent application WO2007/057447. May 24, 2007
121. Brown WD, Teuber, L, Dahl B. Neurosearch A/S. Novel KCNQ channel modulating compounds and their use. United States patent application WO2004/080377. September 23, 2004
122. Attali B, Peretz, A. Ramot AT Tel Aviv University Ltd. Derivatives of N-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/ or cortical neuron activity modulators. United States patent application WO2004/035037. April 29, 2004
123. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, et al. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol 2005; 67(4): 1053-66.
124. Peretz A, Sheinin A, Yue C, Degani-Katzav N, Gibor G, Nachman R, et al. Pre- and postsynaptic activation of M-channels by a novel opener dampens neuronal firing and transmitter release. J Neurophysiol 2007; 97(1): 283-95.
125. Welmaker GS, Wilson MA, McFarlane GR, Sabalski JE, Butera JA, Trybulski; EJ, Herbst DR;. Wyeth. Benzofurans as potassium channel modulators. United States patent application WO2008/0027049. January 31, 2008
126. Wilson MA, Welmaker GS, Trybulski EJ, Butera JA, Magolda RL; Wyeth. Tetracyclic indoles as potassium channel modulators. United States patent application WO2008/0027090. January 31, 2008.
127. Li, M, Sun H, Xiong Q; The John Hopkins University. Method of treating KCNQ related disorders using organozinc compounds. United States patent application WO2007/087424. August 2, 2007
128. Xiong Q, Sun H, Li M. Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol 2007; 3(5): 287-96.
129. Kharkovets T, Dedek K, Maier H, Schweizer M, Khimich D, Nouvian R, et al. Mice with altered KCNQ4 K+ channels implicate sensory outer hair cells in human progressive deafness. Embo J 2006; 25(3): 642-52.
130. Brown DA, Adams PR. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature 1980; 283(5748): 673-6.
131. Mochidome T, Ishibashi H, Takahama K. Bradykinin activates airway parasympathetic ganglion neurons by inhibiting M-currents. Neuroscience 2001; 105(3): 785-91.
132. Yeung S, Schwake M, Pucovsky V, Greenwood I. Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents. Br J Pharmacol 2008; 155(1): 62-72.
133. Yeung SY, Lange W, Schwake M, Greenwood IA. Expression profile and characterisation of a truncated KCNQ5 splice variant. Biochem Biophys Res Commun 2008; 371(4): 741-6.
134. Yeung SY, Pucovsky V, Moffatt JD, Saldanha L, Schwake M, Ohya S, et al. Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol 2007; 151(6): 758-70.
135. Mackie AR, Byron KL. Cardiovascular KCNQ (Kv7) Potassium Channels: Physiological Regulators and New Targets for Therapeutic Intervention. Mol Pharmacol 2008.
136. Argentieri TM, Sheldon JH; Wyeth. Methods of selecting compounds for modulation of bladder function. United States patent US20077160684. January 9, 2007.
137. Jensen HS, Callo K, Jespersen T, Jensen BS, Olesen SP. The KCNQ5 potassium channel from mouse: A broadly expressed Mcurrent like potassium channel modulated by zinc, pH, and volume changes. Brain Res Mol Brain Res 2005; 139(1): 52-62.
138. Gopalakrishnan M, Shieh CC. Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders. Expert Opin Ther Targets 2004; 8(5): 437-58.
139. Streng T, Christoph T, Andersson KE. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol 2004; 172(5 Pt 1): 2054-8.
140. Max MB, Stewart WF. The molecular epidemiology of pain: A new discipline for drug discovery. Nat Rev Drug Discov 2008; 7(8): 647-58.
141. Starowicz K, Cristino L, Di Marzo V. TRPV1 receptors in the central nervous system: Potential for previously unforeseen therapeutic applications. Curr Pharm Des 2008; 14(1): 42-54.
142. Willis CL, Davis TP. Chronic inflammatory pain and the neurovascular unit: A central role for glia in maintaining BBB integrity? Curr Pharm Des 2008; 14(16): 1625-43.